Overview * BioXcel Q3 2025 revenue and net income miss analyst expectations * Company plans sNDA submission for BXCL501 in Q1 2026 * BioXcel advances late-stage clinical trials for BXCL501 Outlook * BioXcel plans to submit an sNDA for IGALMI® in Q1 2026 * Company preparing for TRANQUILITY In-Care Phase 3 Trial * BioXcel sees U.S. at-home agitation market at...

07:08 AM EST, 11/12/2025 (MT Newswires) -- Pharvaris ( PHVS ) late Wednesday reported a Q3 net loss of 0.60 euros ($0.69) per diluted share, narrower than a loss of 0.77 euro a year earlier. Analysts polled by FactSet expected a 0.67 euros per share loss. As of Sept. 30, the company said its cash and cash equivalents were 329...

Overview * Radcom ( RDCM ) Q3 revenue grows 16% yr/yr, beating analyst expectations * Company achieves highest operating margin in seven years, driven by AI and 5G adoption * Radcom ( RDCM ) reaffirms full-year 2025 guidance of 15%-18% revenue growth Outlook * Radcom ( RDCM ) reaffirms full-year 2025 revenue growth guidance of 15%-18% * Company maintains strong...

07:09 AM EST, 11/12/2025 (MT Newswires) -- Aimia ( AIMFF ) on Wednesday reported that its third-quarter revenue fell 2.1% year over year, citing unfavorable economic and market conditions that affected its Bozzetto and Cortland segments. Revenue came in at C$126.4 million, down from $129.1 million. The company cited a backdrop of increased competitive pressure and softer demand in certain...